文献速递咽喉与嗓音

自体肌源性细胞治疗头颈癌治疗后吞咽障碍

Autologous Muscle-Derived Cell Therapy for Swallowing Impairment in Patients Following Treatment for Head and Neck Cancer.
PubMed 文献 · Laryngoscope · 2021-05-14

这项I期开放标签临床试验评估了口咽癌放化疗后吞咽障碍患者舌内注射自体肌源性细胞(AMDCs)的安全性。10例患者注射150×10^6个AMDCs后随访24个月,未发生严重不良事件,平均舌压显著提高,但吞咽功能部分指标未显著改善。

要点

  • 舌内注射150×10^6 AMDCs在口咽癌幸存者中未发生严重不良事件。
  • 吞咽造影渗透-误吸评分和FOIS无显著变化,EAT-10亦无显著变化。

核心结论

  • I期试验表明舌内注射150×10^6 AMDCs安全,可能改善舌 strength 并持续2年,需盲法安慰剂对照试验验证。

研究设计与样本

  • 前瞻性I期开放标签临床试验,招募口咽癌放化疗后无病生存≥2年、吞咽障碍但非管饲依赖(FOIS≥5)的幸存者10例。

主要发现

  • 10例患者中100%(10/10)为男性,平均年龄65(±8.87)岁。
  • 平均渗透-误吸评分从5.6(±2.1)至6.8(±1.8)无显著变化,平均FOIS从5.4(±0.5)至4.6(±0.7)无显著变化。

临床怎么用

  • 该I期结果支持AMDCs舌内注射安全性,舌压改善可能为临床获益方向,但吞咽功能客观指标未显著改善,需进一步盲法对照试验确认疗效。

局限性

  • 样本量小(n=10)且全部为男性,缺乏对照组,为开放标签设计,证据级别为3。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To evaluate the safety and potential efficacy of autologous muscle-derived cells (AMDCs) for the treatment of swallowing impairment following treatment for oropharynx cancer. STUDY DESIGN: Prospective, phase I, open label, clinical trial. METHODS: Oropharynx cancer survivors disease free ≥2 years post chemoradiation were recruited. All patients had swallowing impairment but were not feeding tube dependent (Functional Oral Intake Scale [FOIS] ≥ 5). Muscle tissue (50-250 mg) was harvested from the vastus lateralis and 150 × 106 AMDCs were prepared (Cook MyoSite Inc., Pittsburgh, PA). The cells were injected into four sites throughout the intrinsic tongue musculature. Participants were followed for 24 months. The primary outcome measure was safety. Secondary endpoints included objective measures on swallowing fluoroscopy, oral and pharyngeal pressure, and changes in patient-reported outcomes. RESULTS: Ten individuals were enrolled. 100% (10/10) were male. The mean age of the cohort was 65 (±8.87) years. No serious adverse event occurred. Mean tongue pressure increased significantly from 26.3 (±11.1) to 31.8 (±9.5) kPa (P = .017). The mean penetration-aspiration scale did not significantly change from 5.6 (±2.1) to 6.8 (±1.8), and the mean FOIS did not significantly change from 5.4 (±0.5) to 4.6 (±0.7). The incidence of pneumonia was 30% (3/10) and only 10% (1/10) experienced deterioration in swallowing function throughout 2 years of follow-up. The mean eating assessment tool (EAT-10) did not significantly change from 24.1 (±5.57) to 21.3 (±6.3) (P = .12). CONCLUSION: Results of this phase I clinical trial demonstrate that injection of 150 × 106 AMDCs into the tongue is safe and may improve tongue strength, which is durable at 2 years. A blinded placebo-controlled trial is warranted. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:523-527, 2022.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Nativ-Zeltzer N, Kuhn MA, Evangelista L, et al. Autologous Muscle-Derived Cell Therapy for Swallowing Impairment in Patients Following Treatment for Head and Neck Cancer. Laryngoscope. 2021. PMID: 33988246. doi:10.1002/lary.29606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。